NCT02639091已完成1 期
An Open Label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 in Subjects With Mesothelin-expressing Predominantly Epithelial Mesothelioma or Nonsquamous Non-small-cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 36
- 主要终点
- Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability
研究概览
简要总结
Determine the safety, tolerability and maximum tolerated dose of anetumab ravtansine (BAY 94-9343) in combination with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 in subjects with mesothelin-expressing predominantly epithelial mesothelioma or nonsquamous non-small-cell lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects may be male or female, and must be aged =/>18 years on the date of signing the informed consent form.
- •Subjects must have histologically confirmed, unresectable, locally advanced or metastatic pleural or peritoneal predominantly (>50% of tumor component) epithelial mesothelioma or nonsquamous non-small-cell lung cancer (NSCLC). Both chemotherapy-naive and previously treated subjects will be eligible; however, newly diagnosed NSCLC subjects eligible for FDA-approved therapies should have received the same before enrollment (e.g. subjects with epidermal growth factor receptor [EGFR]-mutated and anaplastic lymphoma kinase [ALK]-translocated NSCLC should have received FDA-approved targeted therapies).
- •Subjects must have at least 1 measurable or evaluable tumor lesion according to RECIST 1.1 (for nonsquamous NSCLC) or mRECIST (for epithelial pleural mesothelioma). Subjects with resected primary tumors who have documented metastases are eligible.
- •Subjects must have a life expectancy of at least 12 weeks.
- •Subjects must have ECOG (Eastern Cooperative Oncology Group performance Status of 0 or 1
- •Subjects must have adequate bone marrow, liver, kidney, and coagulation functions.
排除标准
- •Subjects who have a previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, or any previous cancer curatively treated >3 years before the start of study Treatment.
- •Subjects who have a history or current evidence of bleeding disorder, i.e. any hemorrhage / bleeding event of CTCAE (Common Terminology Criteria for Adverse Events) Grade ≥2 within 4 weeks before the start of study Treatment.
- •Subjects who have new or progressive brain or meningeal or spinal metastases.
- •Subjects who have a history or current evidence of uncontrolled cardiovascular disease i.e. NYHA (New York Heart Association) Class III or IV.
- •Subjects who have a history or current evidence of uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg at screening despite optimal medical management.
- •Subjects who have a history or current evidence of malignant biliary obstruction requiring biliary stent.
- •Subjects who have had solid organ or bone marrow Transplantation.
- •Subjects who have a history of hypersensitivity to any of the study drugs or their excipients, or a history of severe hypersensitivity to any other Antigen.
- •Subjects who have a history of human immunodeficiency virus (HIV) infection or subjects who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment.
- •Subjects who have an active clinically serious infection of CTCAE Grade ≥2 or non-healing wound unrelated to the primary Tumor.
- •Subjects who have received systemic cancer therapy, radiotherapy, investigational drug treatment outside of this study within 4 weeks before the start of study treatment, granulocyte colony stimulating factors, (G-CSF) or granulocyte macrophage-stimulating factors (GM-CSF), erythropoietin-stimulating agents within 3 weeks before the start of general screening, drugs with known renal toxicity and strong cytochrome P450 3A4 (CYP3A4) inhibitors or strong CYP3A4 inducers within 2 weeks before the treatment.
- •Subjects who have started oral or parenteral anticoagulation therapy within 2 weeks before the start of anetumab ravtansine until end of treatment visit.
研究组 & 干预措施
BAY 94-9343 + Pemetrexed + Cisplatin
Experimental
Investigating the combination of anetumab ravtansine (BAY 94-9343) with Pemetrexed (500 mg/m2) and Cisplatin (75 mg/m2) in Part 1 (dose escalation cohorts) and Part 2 (two MTD expansion cohorts)
干预措施: BAY 94-9343 (Drug)
BAY 94-9343 + Pemetrexed + Cisplatin
Experimental
Investigating the combination of anetumab ravtansine (BAY 94-9343) with Pemetrexed (500 mg/m2) and Cisplatin (75 mg/m2) in Part 1 (dose escalation cohorts) and Part 2 (two MTD expansion cohorts)
干预措施: Pemetrexed (Drug)
BAY 94-9343 + Pemetrexed + Cisplatin
Experimental
Investigating the combination of anetumab ravtansine (BAY 94-9343) with Pemetrexed (500 mg/m2) and Cisplatin (75 mg/m2) in Part 1 (dose escalation cohorts) and Part 2 (two MTD expansion cohorts)
干预措施: Cisplatin (Drug)
结局指标
主要结局
Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability
时间窗: Up to 2 years
Maximum tolerated dose (MTD)
时间窗: Up to 2 years
MTD is defined as the highest dose of oral anetumab ravtansine (BAY 94-9343) administered in combination with IV pemetrexed and cisplatin that can be given such that not more than 1 of 6 subjects at a given dose level experience a DLT (dose-limiting toxicity).
次要结局
- Plasma concentrations of anetumab ravtansine (BAY 94-9343), pemetrexed and cisplatin(- BAY 94-9343: C1D1,D2,D3,D8,D15, C2D1, C3D1,D2,D3,D8,D15, C4D1, C6D1 and subsequent cycles every 3rd cycle up to 2 years or until discontinuation of study treatment, whichever comes first - Pemetrexed: C1D1, D2, D3 - Cisplatin: C1D1, D2, D3)
- Tumor response evaluation following mRECIST criteria to determine the number of patients with CR, PR, SD or PD(Baseline, every 8 weeks up to cycle 12; then every 12 weeks from cycle 13 up to 2 years, or until discontinuation of study treatment, whichever comes first)
- Number of patients with a positive titer of anti-drug antibodies(Day1 of C1, C3, C6 and subsequent cycles every 3rd cycle up to 2 years or until discontinuation of study treatment, whichever comes first)
研究者
相似试验
已完成
1 期
Phase I Study of Anetumab Ravtansine in Hepatic or Renal ImpairmentNeoplasmsNCT02696642Bayer54
进行中（未招募）
1 期
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing CancersSolid TumorsNCT03448042Genentech, Inc.123
已完成
1 期
Gene Therapy for Blindness Caused by ChoroideremiaChoroideremiaNCT01461213University of Oxford14
已完成
1 期
BAY80-6946 Open Label, Phase I Study in Patients With Advanced CancerNeoplasmsNCT00962611Bayer57
已完成
1 期
Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung CancerCarcinoma, Non-Small-Cell LungNCT02211833Boehringer Ingelheim41